Efanesoctocog alpha is a factor a replacement therapy designed to decouple recombinant factor VIII from endogenous Willebrand’s factor and overcome the VWF imposed half life ceiling.
Efanesoctocog alpha is a high sustained Factor VIII replacement therapy designed to decouple recombinant Factor VIII from endigenous von Willebrand factor and overcome the von Willebrand factor imposed half-life ceiling.
Efanesoctocog alpha in severe hemophilia A provided once weekly had superior bleeding prevention to pre-study prophylaxis, normal to near normal factor VIII activity and improvements in physical health, pain, and joint health.
Efanesoctocog alpha is composed of a single recombinant factor VIII protein and three additional components that contribute to its increased half-life.
In children with severe hemophilia prophylactic therapy once a week with Efanesoctocog alpha provided sustained Factor VIII activity to the normal or near normal range of greater than 40 international units per deciliter for three days and more than 10 units per deciliter for almost 7 days after it administration: it led to effective bleeding prevention EXTEND-Kids trial group).